BerandaFTRE • NASDAQ
add
Fortrea Holdings Inc
Tutup sebelumnya
$20,69
Rentang hari
$20,87 - $21,60
Rentang tahun
$16,53 - $41,02
Kapitalisasi pasar
1,84Â M USD
Volume Rata-Rata
1,33Â jt
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Dalam berita
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
(USD) | Sep 2024info | Perubahan Y/Y |
---|---|---|
Pendapatan | 674,90Â jt | -5,45% |
Biaya operasional | 157,50Â jt | 21,53% |
Laba bersih | -27,90Â jt | -99,29% |
Margin laba bersih | -4,13 | -110,71% |
Penghasilan per saham | 0,23 | -4,17% |
EBITDA | 12,00Â jt | -72,22% |
Tarif pajak efektif | 48,32% | — |
Neraca
Total aset
Total liabilitas
(USD) | Sep 2024info | Perubahan Y/Y |
---|---|---|
Investasi tunai jangka pdk | 105,30Â jt | -4,01% |
Total aset | 3,66Â M | -15,13% |
Total liabilitas | 2,15Â M | -18,01% |
Total ekuitas | 1,51 M | — |
Saham yang beredar | 89,70 jt | — |
Harga terhadap nilai buku | 1,23 | — |
Tingkat pengembalian aset | -0,64% | — |
Tingkat pengembalian modal | -0,85% | — |
Arus Kas
Perubahan kas bersih
(USD) | Sep 2024info | Perubahan Y/Y |
---|---|---|
Laba bersih | -27,90Â jt | -99,29% |
Kas dari operasi | -2,40Â jt | -226,32% |
Kas dari investasi | -8,10Â jt | -400,00% |
Kas dari pembiayaan | -14,00Â jt | -81,82% |
Perubahan kas bersih | -20,90Â jt | -309,80% |
Arus kas bebas | -19,35Â jt | -269,37% |
Tentang
Fortrea Holdings Inc. is a contract research organization organized in Delaware and headquartered in Durham, North Carolina with operations in 90 countries. Its customers are primarily in the pharmaceutical, biotechnology, and medical device industries.
Its primary business is handling all aspects of clinical trials including phase I through IV clinical trial management, clinical pharmacology, and post-approval services. It handles regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. It focuses on oncology, central nervous system and neurodegenerative, rare diseases, and cell and gene therapies. In the five years ending in 2023, it conducted more than 5,850 clinical trials involving over 1 million subjects. It also conducted over 600 studies for medical device companies.
The company is one of the largest participants in the international primate trade and has been criticized for its animal testing practices, most specifically animal testing on non-human primates. Wikipedia
Didirikan
Apr 1996
Situs
Karyawan
15.500